These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26242375)

  • 1. Phosphodiesterase type 5 inhibitors and kidney disease.
    Afsar B; Ortiz A; Covic A; Gaipov A; Esen T; Goldsmith D; Kanbay M
    Int Urol Nephrol; 2015 Sep; 47(9):1521-8. PubMed ID: 26242375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reno-protective effects of Phosphodiesterase 5 inhibitors.
    Coskuner ER; Ozkan B
    Clin Exp Nephrol; 2021 Jun; 25(6):585-597. PubMed ID: 33754203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How to Retard Progression of Chronic Kidney Disease].
    Schneider MP; Hilgers KF
    Dtsch Med Wochenschr; 2017 Sep; 142(17):1282-1289. PubMed ID: 28850965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
    Gentile G; Remuzzi G; Ruggenenti P
    Nephron; 2015; 129(1):39-41. PubMed ID: 25531311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
    Sarafidis PA; Ruilope LM
    Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
    Scheele W; Diamond S; Gale J; Clerin V; Tamimi N; Le V; Walley R; Grover-Páez F; Perros-Huguet C; Rolph T; El Nahas M
    J Am Soc Nephrol; 2016 Nov; 27(11):3459-3468. PubMed ID: 27113485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the renin angiotensin system for remission/regression of chronic kidney disease.
    Macconi D
    Histol Histopathol; 2010 May; 25(5):655-68. PubMed ID: 20238303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
    Rutkowski B; Tylicki L
    J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
    Fraune C; Lange S; Krebs C; Hölzel A; Baucke J; Divac N; Schwedhelm E; Streichert T; Velden J; Garrelds IM; Danser AH; Frenay AR; van Goor H; Jankowski V; Stahl R; Nguyen G; Wenzel UO
    Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
    Oh YJ; Kim SM; Shin BC; Kim HL; Chung JH; Kim AJ; Ro H; Chang JH; Lee HH; Chung W; Lee C; Jung JY
    PLoS One; 2017; 12(1):e0170874. PubMed ID: 28122064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?
    Yildirim T; Arici M; Piskinpasa S; Aybal-Kutlugun A; Yilmaz R; Altun B; Erdem Y; Turgan C
    Ren Fail; 2012; 34(9):1095-9. PubMed ID: 22950572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and optimization strategies for the development of new drugs that treat chronic kidney disease.
    Ramos AM; Fernández-Fernández B; Pérez-Gómez MV; Carriazo Julio SM; Sanchez-Niño MD; Sanz A; Ruiz-Ortega M; Ortiz A
    Expert Opin Drug Discov; 2020 Jan; 15(1):101-115. PubMed ID: 31736379
    [No Abstract]   [Full Text] [Related]  

  • 17. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.
    Benigni A; Buelli S; Kohan DE
    Pediatr Nephrol; 2021 Apr; 36(4):763-775. PubMed ID: 32185491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease.
    Shirazian S; Grant CD; Mujeeb S; Sharif S; Kumari P; Bhagat M; Mattana J
    Am J Med Sci; 2015 Jun; 349(6):510-5. PubMed ID: 26030613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.